Kit for differentiating organoid containing heart and liver cells

By gradually inducing pluripotent stem cell differentiation in specific culture media and matrix gel, organoids containing heart and liver cells were successfully formed, which solved the problem of difficulty in preparing such cellular organs in the prior art, and provided an effective research model.

CN119020272APending Publication Date: 2024-11-26SHENZHEN PEOPLES HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310588834.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prepare organoids containing heart cells and liver cells as a research model for the fate of early embryonic development cells.

Method used

By culturing pluripotent stem cells in a specific culture medium and wrapping them in matrix gel, differentiation is gradually induced, and organoids containing heart and liver cells are gradually formed using a variety of biochemical factors such as CHIR99021, BMP4, Activin A, etc.

Benefits of technology

Successfully inducing differentiation in vitro to form tissues containing cardiomyocytes, endothelial cells and hepatocytes, provides a powerful research tool with good application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004244780050000011
    Figure HDA0004244780050000011
  • Figure HDA0004244780050000012
    Figure HDA0004244780050000012
  • Figure HDA0004244780050000021
    Figure HDA0004244780050000021
Patent Text Reader

Abstract

The invention discloses a kit for differentiating organoid containing heart and liver cells. The kit disclosed by the invention contains a culture medium 1, a culture medium 2 and a culture medium 3, a solvent of each culture medium is an RPMI1640 culture medium, solutes of the culture medium 1 are 5 [mu] mol of CHIR99021, 2% of B27, 550 [mu] g / mL of L-ascorbic acid-2-trisodium phosphate and 0.5 [mu] mol of BMP4, solutes of the culture medium 2 are 2.5 [mu] mol of KY02111, 2% of B27, 550 [mu] g / mL of L-ascorbic acid-2-trisodium phosphate and 5 [mu] mol of Activin A, and solutes of the culture medium 3 are 2% of B27, 550 [mu] g / mL of L-ascorbic acid-2-trisodium phosphate and 1% of KOSR. By utilizing the kit provided by the invention, the pluripotent stem cells can be induced and differentiated into organoid containing heart and liver cells in vitro.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a kit for differentiating organoids containing heart and liver cells in the field of biomedicine. Background Art

[0002] Organoids are three-dimensional assemblies of cells that contain more than one cell type and exhibit at least some of the physiological characteristics of the organ to which the cells belong.

[0003] During embryonic development, paracrine signaling between the mesoderm and endoderm plays a key role in determining the fate and functional maturation of the heart and liver. Organoids containing heart and liver cells provide a valuable model to improve the understanding of cell fate in early embryonic development and can serve as a powerful tool for mechanistic studies.

[0004] Human pluripotent stem cells include human embryonic stem cells and human induced pluripotent stem cells, which have unlimited proliferation ability and can differentiate into almost all human cells in vitro, including heart and liver cells. Human pluripotent stem cells are an ideal source of seed cells for building organoids. Summary of the invention

[0005] The technical problem to be solved by the present invention is how to prepare organoids containing heart cells and liver cells.

[0006] In order to solve the above technical problems, the present invention first provides a method for preparing organoids containing heart cells and liver cells, the method comprising:

[0007] 1) culturing pluripotent stem cells in culture medium 0 to obtain pluripotent stem cell spheres; the culture medium 0 is a human pluripotent stem cell culture medium containing Y27632;

[0008] 2) placing the pluripotent stem cell sphere in matrix gel until the matrix gel solidifies to obtain pluripotent stem cell spheres wrapped in matrix gel; placing the pluripotent stem cell spheres wrapped in matrix gel in culture medium 1 to obtain pluripotent stem cell spheres cultured in culture medium 1; the culture medium 1 is composed of a solvent and a solute, the solvent is RPMI1640 culture medium, and the solute and its concentration are 5 μmol CHIR99021, 2% (volume percentage) B27, 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt and 0.5 μmol BMP4 (bone morphogenetic protein 4);

[0009] 3) placing the pluripotent stem cell spheres cultured in the culture medium 1 in matrigel until the matrigel solidifies to obtain pluripotent stem cell spheres cultured in the culture medium 1 wrapped in matrigel; placing the pluripotent stem cell spheres cultured in the culture medium 1 wrapped in matrigel in culture medium 2 to obtain pluripotent stem cell spheres cultured in the culture medium 2; the culture medium 2 is composed of a solvent and a solute, the solvent is RPMI1640 culture medium, and the solute and its concentration are 2.5 μmol KY02111, 2% (volume percentage) B27, 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt and 5 μmol Activin A respectively;

[0010] 4) The pluripotent stem cell spheres cultured in the culture medium 2 are placed in the culture medium 3 for culture to obtain organoids containing heart cells and liver cells; the culture medium 3 is composed of a solvent and a solute, the solvent is RPMI1640 culture medium, and the solute and its concentration are 2% (volume percentage) B27, 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt and 1% (volume percentage) KOSR (serum replacement), respectively.

[0011] In the above method, the matrix gel-wrapped pluripotent stem cell spheres may be cultured in the culture medium 1 for 48 hours.

[0012] In the above method, the culture time of the pluripotent stem cell spheres cultured in the culture medium 1 wrapped with the matrix gel in the culture medium 2 can be 48 hours.

[0013] In the above method, the pluripotent stem cell spheres cultured in the culture medium 2 may be cultured in the culture medium 3 for a period of time greater than or equal to 6 days.

[0014] In the above method, the concentration of Y27632 in the culture medium 0 may be 5-10 μmol.

[0015] In the above method, the pluripotent stem cells may be embryonic stem cells or induced pluripotent stem cells. Further, the pluripotent stem cells may be mammalian embryonic stem cells or induced pluripotent stem cells.

[0016] Furthermore, the mammal is a human. In one embodiment of the present invention, the human embryonic stem cell is H9.

[0017] The present invention also provides a kit for preparing organoids containing cardiac cells and liver cells, wherein the kit contains the culture medium 1, the culture medium 2 and the culture medium 3.

[0018] The above kit also contains the culture medium 0.

[0019] The above-mentioned kit may be composed of the culture medium 1, the culture medium 2 and the culture medium 3, or may be composed of the culture medium 1, the culture medium 2, the culture medium 3 and the culture medium 0. Each culture medium may be packaged independently.

[0020] The use of the kit in preparing organoids containing heart cells and liver cells also falls within the protection scope of the present invention.

[0021] In the embodiment of the present invention, CHIR99021 is a selleck product with the product number S1263.

[0022] B27 is a LIFE product, item number A1895601.

[0023] L-ascorbic acid-2-phosphate trisodium salt (LAAP) is a Sigma product with a product number of 49752.

[0024] BMP4 (Bone Morphogenetic Protein 4) is a STEM CELL product with the catalog number 78211_C.

[0025] KY02111 is a selleck product, item number is S7096.

[0026] Activin A is a Sigma product, item number 49752.

[0027] KOSR (serum replacement) is a product of ThermoFisher, product number 10828028.

[0028] In the present invention, the organoid may be a tissue containing cardiomyocytes, endothelial cells and hepatocytes.

[0029] The methods of the present invention are performed in vitro.

[0030] The method of the present invention can induce pluripotent stem cells to differentiate into organoids containing heart and liver cells in vitro, and has good application prospects.

[0031] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 .Cardiac organoid differentiation process and representative views.

[0033] Figure 2 .Organoid identification results.

[0034] Figure 3 .Comparative experimental results. DETAILED DESCRIPTION

[0035] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, instruments, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0036] In the following examples, unless otherwise specified, all were carried out under sterile conditions, and the culture conditions were all 37° C. and 5% CO 2 .

[0037] Embodiment 1,

[0038] 1. Culture of Embryonic Stem Cells

[0039] 1) Human embryonic stem cells H9 (Cell Bank of Typical Culture Collection Committee of Chinese Academy of Sciences, 18-1-1522) were inoculated in a culture plate pre-coated with Matrigel (Matrigel, Corning, 354277) (Note: Matrigel here needs to be diluted with sterile PBS solution, the dilution ratio is 1:500), and then Ⅱ Human pluripotent stem cell culture medium (Saibei Bio, CA1014500) (other stem cell culture media can also be used here, such as life E8, STEM CELL mTesR1), and the medium was changed every day.

[0040] 2) When the cell confluence reaches 80%, the cells need to be subcultured. Use human pluripotent stem cell digestion solution (Cibel Biotech CA3001500) or 0.25mM EDTA to perform subculture according to the instructions.

[0041] 2. Organoid Differentiation Steps

[0042] 1) Count the cells digested in step 1 using trypan blue. Take 100,000 cells and inoculate them in a 96-well U-shaped low-adsorption cell culture plate (Qingdao Jindian Biochemical Equipment Co., Ltd., 16196-6SULH). Use 100 μl of human pluripotent stem cell culture medium and add 5 μmol Y27632 (selleck, S6390) to culture for 24 hours. After 24 hours, human embryonic stem cell spheres were obtained, such as Figure 1 Shown in B (Day 0).

[0043] 2) Aspirate the culture medium in step 1) and add 3-5 μL Matrigel stock solution to each well to ensure that the human embryonic stem cell spheres are all wrapped in Matrigel liquid. Then put the cell plate back into the cell culture incubator for 60 minutes to allow Matrigel to solidify.

[0044] 3) After 60 minutes, take out the cell culture plate, add 200 μl of culture medium 1 to each well, return to the cell culture incubator, and continue to culture for 48 hours. Culture medium 1: RPMI1640 culture medium + 5 μmol CHIR99021 (selleck, S1263) + 2% (volume percentage) B27 (LIFE, A1895601) + 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt (LAAP, sigma, 49752) + 0.5 μmol BMP4 (Bone Morphogenetic Protein 4, STEM CELL product, catalog number 78211_C).

[0045] 4) After 48 hours, remove the cell culture plate and discard the medium 1. Add 3-5 μL Matrigel stock solution to each well to ensure that the cell spheres are wrapped in Matrigel liquid. Then put the cell plate back into the cell culture incubator for 60 minutes to allow Matrigel to solidify.

[0046] 5) After 60 minutes, take out the cell culture plate, add 200 μl of medium 2 to each well, return to the cell culture incubator, and continue to culture for 48 hours. Medium 2: RPMI1640 medium + 2.5 μmol KY02111 (selleck, S7096) + 2% (volume percentage) B27 (LIFE, A1895601) + 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt + 5 μmol Activin A (sigma, 49752).

[0047] 6) After 48 hours, remove the cell culture plate and discard medium 2. Add 200 μl of medium 3 to each well, return to the cell culture incubator, and culture for 48 hours. Thereafter, replace medium 3 every 2 days. Beating organoids appeared on days 10-12. The composition of medium 3 is: RPMI1640 medium + 2% (volume percentage) B27 (LIFE, A1895601) + 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt (sigma, 49752) + 1% (volume percentage) KOSR (serum replacement) (ThermoFisher product, catalog number 10828028).

[0048] 3. Organoid Identification

[0049] Figure 1 This is the organoid differentiation process and representative views.

[0050] HE staining showed that the constructed organoids contained liver cell-derived endoderm structures ( Figure 2 (A).

[0051] The organoids were subjected to single-cell sequencing analysis, and the UMAP results showed that the organoids were rich in a variety of cardiac cells such as cardiomyocytes, cardiac fibroblasts, endothelial cells, and liver cells (Hepatocytes C1 and Hepatocytes C2) ( Figure 2 (middle B).

[0052] Immunofluorescence results showed that the organoids expressed the cardiomyocyte marker TNNT2, endothelial cell marker PECAM1, and hepatocyte marker VIM ( Figure 2 Middle C), indicating that the obtained organoids have cardiomyocytes (TNNT2), endothelial cells (PECAM1) and hepatocytes (VIM). The antibodies used are TNNT2 (Santa Cruz, sc-20025), PECAM1 antibody (ThermoFisher, 14-0319-82) and VIM (Abcam, EPR3776).

[0053] Comparative ratio,

[0054] According to the method of Example 1, on the second day of differentiation, if matrigel is not used for wrapping for 1 hour, the organoid cells obtained will disperse and form single cells, and ultimately fail to form a 3D organoid structure, and the cells will gradually die ( Figure 3 ).

[0055] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A method for preparing an organoid containing cardiac cells and liver cells, comprising: 1) Cultivating pluripotent stem cells in culture medium 0 to obtain pluripotent stem cell spheres; The medium 0 is a human pluripotent stem cell medium containing Y27632; 2) placing the pluripotent stem cell sphere in matrigel until the matrigel solidifies to obtain pluripotent stem cell spheres wrapped in matrigel; placing the pluripotent stem cell spheres wrapped in matrigel in culture medium 1 for culture to obtain pluripotent stem cell spheres cultured in culture medium 1; the culture medium 1 is composed of a solvent and a solute, the solvent is RPMI1640 culture medium, the solute and its concentration are 5 μmol CHIR99021, 2% (volume percentage) B27, 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt and 0.5 μmol BMP4 respectively; 3) placing the pluripotent stem cell spheres cultured in the culture medium 1 in matrigel until the matrigel solidifies to obtain pluripotent stem cell spheres cultured in the culture medium 1 wrapped in matrigel; placing the pluripotent stem cell spheres cultured in the culture medium 1 wrapped in matrigel in culture medium 2 to obtain pluripotent stem cell spheres cultured in the culture medium 2; the culture medium 2 is composed of a solvent and a solute, the solvent is RPMI1640 culture medium, and the solute and its concentration are 2.5 μmol KY02111, 2% (volume percentage) B27, 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt and 5 μmol Activin A respectively; 4) The pluripotent stem cell spheres cultured in the culture medium 2 are placed in the culture medium 3 for culture to obtain organoids containing heart cells and liver cells; the culture medium 3 is composed of a solvent and a solute, the solvent is RPMI1640 culture medium, and the solute and its concentration are 2% (volume percentage) B27, 550 μg / mL L-ascorbic acid-2-phosphate trisodium salt and 1% (volume percentage) KOSR.

2. The method according to claim 1, characterized in that: The matrix gel-encapsulated pluripotent stem cell spheres were cultured in the culture medium 1 for 48 hours.

3. The method according to claim 1 or 2, characterized in that: The culture time of the pluripotent stem cell spheres cultured in the culture medium 1 wrapped in the matrix gel in the culture medium 2 is 48 hours.

4. The method according to any one of claims 1 to 3, characterized in that: The pluripotent stem cell spheres cultured in the culture medium 2 are cultured in the culture medium 3 for a period of time greater than or equal to 6 days.

5. The method according to any one of claims 1 to 4, characterized in that: The concentration of Y27632 in the culture medium 0 is 5-10 μmol.

6. The method according to any one of claims 1 to 5, characterized in that: The pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells; Furthermore, the pluripotent stem cells are mammalian embryonic stem cells or induced pluripotent stem cells.

7. The method according to claim 6, characterized in that: The mammal is a human.

8. A kit for preparing organoids containing cardiac cells and liver cells, comprising the culture medium 1, the culture medium 2 and the culture medium 3 according to any one of claims 1 to 5.

9. The kit according to claim 8, characterized in that: The kit further comprises the culture medium 0 described in any one of claims 1-5.

10. Use of the kit according to claim 8 or 9 in preparing organoids containing heart cells and liver cells.

Citation Information

Cited By

  • Heart organoid and in-vitro preparation method thereof

    CN119570719A